LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Onconova Therapeutics, Inc. announced today the successful completion of the first dose cohort of a Phase I clinical trial of its novel radioprotective drug ON 01210.Na (Ex-RAD™). A first-in-class radiation protection drug for both prophylactic and therapeutic applications, ON 01210.Na is a modulator of DNA repair pathways and has been shown to enhance survival in animal models of radiation injury. The drug is being developed under the FDA’s Animal Rule which outlines the approval pathway for drugs indicated for protection against harmful agents, including radiation.
